Identification, characterization and quantification of new impurities by LC-ESI/MS/MS and LC-UV methods in rivastigmine tartrate active pharmaceutical ingredient

Journal of Pharmaceutical and Biomedical Analysis

Volumn 57, Issue 1, 2012, Pages 39-51

  Thomas, Saji ^a   Shandilya, Sanjeev ^a   Bharati, Amber ^a   Paul, Saroj Kumar ^a   Agarwal, Ashutosh ^a   Mathela, Chandra S ^b  

^a Jubilant Life Sciences Ltd   (India)

^b KUMAUN UNIVERSITY   (India)

Author keywords

Characterization; Impurity; LC MS MS; Rivastigmine; Validation

Indexed keywords

3 [1 (DIMETHYLAMINO)ETHYL]PHENYL N ETHYL N METHYLCARBAMIC ACID N OXIDE; CARBAMIC ACID METHYL ESTER; ETHYLMETHYLCARBAMIC ACID 2 (1 DIMETHYLAMINOETHYL)PHENYL ESTER; ETHYLMETHYLCARBAMIC ACID 4 (1 DIMETHYLAMINOETHYL)PHENYL ESTER; RIVASTIGMINE; UNCLASSIFIED DRUG;

ACCURACY; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; DRUG IMPURITY; DRUG STRUCTURE; ELECTROSPRAY MASS SPECTROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INFRARED SPECTROSCOPY; MOLECULAR STABILITY; PHOTOCHEMISTRY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; VALIDATION PROCESS;

CHOLINESTERASE INHIBITORS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; MAGNETIC RESONANCE SPECTROSCOPY; PHARMACEUTICAL PREPARATIONS; PHENYLCARBAMATES; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TANDEM MASS SPECTROMETRY;

EID: 80054026312     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2011.08.014     Document Type: Article

References (24)

1. Martindale, The Complete Drug Reference 2009, 369-370. Royal Pharmaceutical Society of Great Britain. 36th ed. J.E.F. Reynolds (Ed.).
2. Cutler N.R., Sramek J.J. Review of the next generation of Alzheimer's disease therapeutics: challenges for drug development. Prog. Neurophyschopharmacol. Biol. Psychiatry 2001, 25:27-57.
3. Casademont J.M.O., Rodriguuez-Santiago B., Videma P., Blesa R., Cardellach F. Cholinesterase inhibitor rivastigmine enhances the mitochondrial electron transport chain in lymphocytes of patients with Alzheimer's disease. J. Neurosci. 2003, 206:23-26.
4. Rao B.M., Srinivasu M.K., Kumar K.P., Bhradwaj N., Ravi R., Mohakhud P.K., Reddy G.O., Kumar P.R. Stability indicating LC method for rivastigmine hydrogen tartrate. J. Pharm. Biomed. Anal. 2005, 37:57-63.
5. Dermiş S. Voltammetric behaviour of rivastigmine hydrogen tartrate and its determination in capsule dosage form. J. Fac. Pharm. 2006, 26:1-12.
6. Srinvasu M.K., Rao M.B., Reddy B.S.S., Kumar P.R., Chandrasekhar K.B., Mohakhud P.K. A validated chiral liquid chromatographic method for the enantiomeric separation of rivastigmine hydrogen tartarate, a cholinesterase inhibitor. J. Pharm. Biomed. Anal. 2005, 38:320-325.
7. Rao M.S., Rao S.V., Rao D.V.N.S., Bharathi Ch., Rajput P., Sharma H.K. Identification and characterization of new impurities in rivastigmine. Pharmazie 2010, 65:336-338.
8. Karthik A., Musmade P., Subramanian G., Kiado M.S. Stability-indicating HPTLC determination of rivastigmine in the bulk drug and in pharmaceutical dosage form. J. Plan. Chromatogr. Mod. 2007, TLC:933-4173.
9. Arumugam K., Chamallamudi M.R., Gilibili R.R., Mullangi R., Ganesan S., Kar S.S., Averineni R., Shavi G., Udupa N. Development and validation of a HPLC method for quantification of rivastigmine in rat urine and identification of a novel metabolite in urine by LC-MS/MS. Biomed. Chromatogr. 2010, 25:353-361.
10. Bhatt J., Subbaiah G., Kambli S., Shah B., Nigam S., Patel M., Saxena A., Baliga A., Parekh H., Yadav G. A rapid and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the estimation of rivastigmine in human plasma. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2007, 852:115-121.
11. United States Pharmacopoeia-34, vol. 3, 2011, pp. 4176-4178.
12. Pharmaeuropa, vol. 23, no. 2, 2011, pp. 379-381.
13. ICH Guidelines, Q3A (R2), Impurities in New Drug Substances, October 25, 2006.
14. Sheldon E.M., Downar J.B. Development and validation of a single robust HPLC method for the characterization of a pharmaceutical starting material and impurities from three suppliers using three separate synthetic routes. J. Pharm. Biomed. Anal. 2000, 23:561-572.
15. Sheldon E.M. Development of a LC-LC-MS complete heart-cut approach for the characterization of a pharmaceutical compounds using standard instrumentation. J. Pharm. Biomed. Anal. 2003, 31:1153-1166.
16. Bartos D., Gorog S. Recent advances in the impurity profiling of drugs. Curr. Pharm. Anal. 2008, 4:215-230.
17. Rao R.N., Nagaraju V. An overview of the recent trends in development of HPLC methods for the determination of impurities in drugs. J. Pharm. Biomed. Anal. 2003, 33:335-377.
18. Determination of Impurities in Drugs 1999, Elsevier Sciences, Amsterdam. S. Gorog (Ed.).
19. Ahuja S. Impurities Evaluation in Pharmaceuticals 1998, Marcel Dekker, New York.
20. Husain S., Rao R.N. Monitoring of process impurities in drugs. Advanced Chromatographic and Electromigration Methods in Biosciences 1998, 834-888. Elsevier Science, Amsterdam. Z. Dey1, I. Miksik, F. Taglirao, E. Tesarova (Eds.).
21. Moraes L.A.B., Sabino A.A., Meurer E.C., Eberlin M.N. Absolute configuration assignment of ortho, meta or para isomers by mass spectrometry. J Am. Soc. Mass Spectrom. 2005, 16:431-436.
22. 2: the positional effect of methoxyl substituent. Int. J. Mass Spectrom. 2011, 299:13-19.
23. Reddy V.V., Rao M.V.N.B., Ganesh V., Kumar A.V., Praveen C., Mukkanti K., Reddy G.M., Reddy G.M. An improved process for the production of rivastigmine tartrate, a cholinesterase inhibitor. Lett. Org. Chem. 2010, 7:149-154.
24. ICH Guidelines, Q2 (R1), Validation of Analytical Procedures: Test and Methodology, November, 2005.